October 19, 2016
FDA approves Roche’s cancer immunotherapy Tecentriq for metastatic NSCLC
FDA approves Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
October 19, 2016
GW Pharmaceutical cancels trading shares on AIM on December 2, 1016, continues trading on NASDAQ
GW Pharmaceuticals plc has announced leaving AIM and canceling trading in London, to continue trading only on NASDAQ.
October 19, 2016
Advandec Oncotherapy’s Harley Street site planning permission granted
Advanced Oncotherapy , the developer of proton therapy systems for cancer treatment, has announced on Tuesday that planning permission for the Harley Street site was granted.
October 19, 2016
Beximco Pharmaceutical to declare cash and stock dividends at next AGM
A Bangladesh based, AIM listed Beximco Pharmaceuticals has announced that it would declare/approve 5% final Cash Dividend, 5% Stock Dividend and 10% Cash Dividend
October 19, 2016
Keopsys group makes changes in Quantel’s Board
KEOPSYS Group holding company, acquired for € 5 million, 93.8% of the capital of EURODYNE, which holds 1,184,513 QUANTEL shares and 1,928,579 voting rights, representing 14.6% of the capital and 21.3% of the voting rights of QUANTEL.
October 19, 2016
Allergan releases its “lip pumping drug” to the US market
Allergan has announced that the latest addition to the Juvederm collection of fillers, Juvederm Volbella XC, is now available to physicians and patients for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as “lipstick lines”, in adults over the age of 21.
October 19, 2016
Quantum Pharma names new CEO and makes other board changes
Quantum Pharma names new CEO and makes other board changes
@qp_group
October 14, 2016
Allergan partners with SonarMD in developing new IBS-D patient engagement platform
Allergan has announced a collaboration with SonarMD on the development of clinical decision support (CDS) and patient engagement tools which can be used to facilitate physician identification of patients suffering from Irritable Bowel Syndrome with Diarrhea (IBS-D) in clinical practice and monitor their treatment outcomes.
October 13, 2016
Horizon Pharma offers $300M senior notes and borrows money for buying Raptor Pharmaceuticals
Horizon Pharma, with its wholly owned subsidiaries, Horizon Pharma, Inc. and Horizon Pharma USA, Inc., intends to offer $300 million aggregate principal amount of senior notes due 2024, and to borrow $375 million.
October 13, 2016
Allergan’s BELKYRA Receives Marketing Authorisation In Sweden
Allergan announced that Sweden has received the Marketing Authorisation for BELKYRA (deoxycholic acid) after being granted approval by the Swedish Medical Products Agency (MPA).